TY - JOUR
T1 - Transplantation without growth factor
T2 - Engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL)
AU - Gertz, M. A.
AU - Lacy, M. Q.
AU - Dispenzieri, A.
AU - Hayman, S. R.
AU - Kumar, S. K.
AU - Leung, N.
AU - Gastineau, D. A.
PY - 2007/11
Y1 - 2007/11
N2 - Stem cell transplantation is increasingly used in the management of immunoglobulin light-chain amyloidosis (AL). It is considered the standard of care to administer growth factors to accelerate neutrophil recovery after transplantation. However, unique toxicities occur with growth factor use in patients with AL who receive a stem cell transplant. We report a cohort of patients who underwent transplantation without receiving posttransplantation growth factors. In total, 282 patients received a stem cell transplant. A neutrophil count of 500/ μl was achieved in 50, 75 and 90% of patients at 14, 16 and 22 days, respectively. A platelet count of 20 000/μl was achieved in 50, 75 and 90% of patients at 14, 20 and 31 days, respectively. Non-staphylococcal bacteremia was detected in 16% of patients. The median hospital stay was 9 days. It is feasible and reasonable to withhold growth factor therapy after autologous stem cell transplantation in patients with AL.
AB - Stem cell transplantation is increasingly used in the management of immunoglobulin light-chain amyloidosis (AL). It is considered the standard of care to administer growth factors to accelerate neutrophil recovery after transplantation. However, unique toxicities occur with growth factor use in patients with AL who receive a stem cell transplant. We report a cohort of patients who underwent transplantation without receiving posttransplantation growth factors. In total, 282 patients received a stem cell transplant. A neutrophil count of 500/ μl was achieved in 50, 75 and 90% of patients at 14, 16 and 22 days, respectively. A platelet count of 20 000/μl was achieved in 50, 75 and 90% of patients at 14, 20 and 31 days, respectively. Non-staphylococcal bacteremia was detected in 16% of patients. The median hospital stay was 9 days. It is feasible and reasonable to withhold growth factor therapy after autologous stem cell transplantation in patients with AL.
UR - http://www.scopus.com/inward/record.url?scp=35748975944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35748975944&partnerID=8YFLogxK
U2 - 10.1038/sj.bmt.1705848
DO - 10.1038/sj.bmt.1705848
M3 - Article
C2 - 17846598
AN - SCOPUS:35748975944
SN - 0268-3369
VL - 40
SP - 989
EP - 993
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 10
ER -